TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA issued final guidance on October 20, 2026, describing how drug companies should handle apps used alongside prescription medicines. It distinguishes software connected to a medical device from standalone apps and explains when apps should appear in prescribing information and how app content may be treated for FDA review.
The U.S. Food and Drug Administration issued final guidance on October 20, 2026, describing how drug companies should develop, distribute and label apps used alongside prescription medicines. The recommendations address when app information may require FDA review, when software should be referenced in a drug’s official prescribing information, and what companies should submit to the agency.
The guidance addresses three questions for industry: whether app content is treated as FDA-required labeling or promotional labeling, when a companion app should be mentioned in prescribing information, and what materials companies should submit when distributing app content to users. The FDA describes the document as a framework for both software tied to a medicine and standalone tools used alongside it.
For apps connected to a medical device—the agency gives an asthma-inhaler app as an example—the FDA says they generally should be described on the drug’s official prescribing label because of the software’s central role in how the medicine is used. For standalone tools such as symptom trackers, dose reminders or health coaching apps, a label reference is recommended if a company can show the app is essential for safe and effective use or can demonstrate a meaningful clinical benefit.
The agency says that, in most cases, content displayed to users by a companion app will be treated as promotional material, consistent with its approach to other drug advertising. The guidance does not say that every app needs to appear on a drug label. It sets out criteria for companies to consider when deciding whether a reference is warranted and what information to provide to FDA.
How App Labels May Change
The recommendations address how drugmakers and technology partners explain digital tools to patients and health professionals. When an app is described in a drug’s official prescribing information, the reference identifies its role in treatment. The FDA’s distinction between device-connected software and standalone apps provides criteria for companies to consider when deciding whether a label mention is appropriate.
The FDA says the guidance is intended to promote accurate, evidence-based information and clear communication with patients and providers. The release does not report a change to any specific product’s approval or labeling, nor does it announce enforcement action. It provides recommendations for future app development, distribution and labeling decisions.
For developers, the guidance describes how the agency intends to handle app content, including the general treatment of user-facing content as promotional material. Drug companies and software partners can consider these recommendations when planning an app, while assessing its specific functions and the evidence supporting its role.
As an affiliate, we earn on qualifying purchases.
The FDA’s Digital Health Framework
The final guidance is part of the FDA’s stated effort to adapt its regulatory approach to digital health technologies. The agency says companion apps are increasingly used to help people manage medicines and health conditions, while software capabilities are moving beyond basic reminders. The release describes the guidance as intended to reduce uncertainty for manufacturers while maintaining existing safety and effectiveness standards.
The agency says the approach aligns oversight across its drug and device centers. For products combining a prescription medicine with software or a medical device, companies may need to consider the software’s connection to the medicine and its function. The FDA’s examples illustrate the distinction, but the release does not provide a product-by-product list or describe how every app category will be handled.
The FDA published the final guidance on October 20, 2026. It follows a period of uncertainty identified in the agency’s announcement about when app content falls under submission requirements and when apps belong on official drug labeling. The source material does not state when the agency began developing the guidance or provide a comparison with a prior draft.
“This guidance helps ensure that the information these tools provide is accurate, evidence-based, and clearly communicated to both patients and their providers.”
— Captain Chris Wheeler, director of the Division of Medical Policy Programs within FDA’s Center for Drug Evaluation and Research
As an affiliate, we earn on qualifying purchases.
Questions for Specific Apps
The guidance provides general recommendations, but the FDA announcement does not resolve how the criteria apply to every individual app. It does not identify specific products that will require label references or submissions, nor does it give a detailed list of the materials companies must submit in each case. Those determinations may depend on an app’s function, its connection to a drug or device, and evidence of its clinical role.
The release also does not describe a compliance deadline, a transition schedule for apps already in use, or new penalties for companies that do not follow the recommendations. The FDA characterizes the document as guidance and offers recommendations; the announcement does not say that every recommendation creates a new binding requirement. Developers and drugmakers will need to consult the full document for details beyond the summary in the press release.
As an affiliate, we earn on qualifying purchases.
Companies Apply the Recommendations
The final guidance is available from the FDA for drug companies and their technology partners to consult when planning app distribution, user-facing content and drug-label references. Firms can assess whether their software connects to a medical device, whether it is essential for safe and effective use, and whether they can demonstrate a meaningful clinical benefit.
The FDA’s announcement does not set out a future rulemaking date or a schedule for additional action. Any specific changes to drug labels or app submissions will depend on company decisions and FDA review. The announcement does not specify the timing or extent of any resulting changes.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the FDA announce?
The FDA issued final guidance on October 20, 2026, explaining how drug companies should address apps used alongside prescription medicines, including app content, FDA submissions and references in prescribing information.
Which companion apps should generally be described on a drug label?
The FDA says apps connected to a medical device, such as an app paired with an asthma inhaler, generally should be described in the drug’s official prescribing information because the software plays a central role in how the medicine is used.
Do standalone medication apps automatically need a label reference?
No. The FDA says standalone apps should be referenced if the company can show they are essential for safe and effective use or demonstrate a meaningful clinical benefit. The guidance does not say every standalone app needs to appear on a drug label.
How does the FDA generally classify content shown in companion apps?
The agency says that, in most cases, content a companion app displays to users will be treated as promotional material, consistent with its approach to other drug advertising.
Does the announcement set a deadline for companies?
The FDA’s announcement does not provide a compliance deadline or schedule for existing apps. It also does not specify which individual products will need changes; companies should consult the full guidance for the agency’s detailed recommendations.
Source: primary
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
